Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Gilead Sciences
AstraZeneca
Hoffmann-La Roche
Bristol-Myers Squibb
Janssen Research & Development, LLC
Regeneron Pharmaceuticals
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
AstraZeneca
Bristol-Myers Squibb
Hoffmann-La Roche
Astellas Pharma Inc
Bristol-Myers Squibb
AstraZeneca
Bristol-Myers Squibb
AstraZeneca
Merck Sharp & Dohme LLC
Tesaro, Inc.
Merck Sharp & Dohme LLC
Astellas Pharma Inc
AstraZeneca
Akeso
Novartis
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Novartis
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
National Cancer Institute (NCI)